NextCure (NXTC) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free NXTC Stock Alerts $1.29 -0.15 (-10.42%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024globenewswire.com - April 24 at 4:05 PMPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Ratingmarkets.businessinsider.com - April 8 at 7:06 PMNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024globenewswire.com - April 8 at 7:00 AMNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Boardglobenewswire.com - April 4 at 7:05 AMNextCure to Present at 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:00 AMNextCure, Inc. (NASDAQ:NXTC) Short Interest Updatemarketbeat.com - March 27 at 10:15 PMWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?finance.yahoo.com - March 27 at 10:07 AMWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Richinvestorplace.com - March 23 at 6:00 AMPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy Ratingmarkets.businessinsider.com - March 22 at 5:19 PMHC Wainwright Boosts NextCure (NASDAQ:NXTC) Price Target to $8.00marketbeat.com - March 22 at 2:58 PMAnalysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)markets.businessinsider.com - March 21 at 9:15 PMNextCure to Cut 37% of Jobs, Will Narrow Focus on Drug Candidatesmarketwatch.com - March 21 at 4:06 PMMd. biopharma lays off staff, pauses manufacturing to preserve cashbizjournals.com - March 21 at 4:06 PMNextCure Provides Business Update and Reports Full Year 2023 Financial Resultsglobenewswire.com - March 21 at 8:55 AMNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advancesglobenewswire.com - March 5 at 8:05 AMNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disordersfinance.yahoo.com - January 18 at 6:56 PMNextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and Datesbenzinga.com - December 28 at 3:49 PMHere's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishingfinance.yahoo.com - December 25 at 2:02 PMNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injuryfinance.yahoo.com - December 21 at 7:59 AMNextCure (NXTC) Down on Shelving Plans to Develop Candidatefinance.yahoo.com - December 15 at 1:35 PMBuy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline Shiftmarkets.businessinsider.com - December 15 at 8:34 AMAnalysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)markets.businessinsider.com - December 15 at 12:33 AMNextCure stock falls 20% amid program shutdown, business updatemsn.com - December 14 at 7:32 PMNextCure Shares Fall 26% After Halting Development of One Drug Candidatemarketwatch.com - December 14 at 9:31 AMNextCure Provides Year-End Clinical Pipeline Updatesfinance.yahoo.com - December 14 at 9:31 AMNextCure to Present at the 35th Annual Piper Sandler Healthcare Conferencefinance.yahoo.com - November 20 at 8:25 AMNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AMLfinance.yahoo.com - November 15 at 8:47 PMNextCure Inc NXTCmorningstar.com - November 12 at 12:46 PMAll You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buymsn.com - November 7 at 1:22 PMNextCure Provides Business Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 2 at 9:02 PMNextCure Inc (NXTC) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 2 at 9:02 PMWe Think NextCure (NASDAQ:NXTC) Needs To Drive Business Growth Carefullyfinance.yahoo.com - October 19 at 10:08 AMPreclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)finance.yahoo.com - October 17 at 9:49 AMNextcure (NXTC) Price Target Increased by 26.67% to 6.46msn.com - October 5 at 8:41 AMNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer's Diseasebenzinga.com - September 26 at 6:20 PMNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Diseasefinance.yahoo.com - September 26 at 6:20 PMA Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLCfinance.yahoo.com - September 12 at 9:55 AMNextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagenfinance.yahoo.com - September 7 at 7:00 PMPreclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Diseasefinance.yahoo.com - September 5 at 6:21 PMNextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - August 31 at 8:12 AMHC Wainwright & Co. Initiates Coverage of Nextcure (NXTC) with Buy Recommendationmsn.com - August 8 at 4:19 PMNextCure Provides Business Update and Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 3 at 4:49 PMNextCure Presents Non-Clinical Data Defining The Mechanism Of NC525 At The 2023 Federation Of Clinical Immunology Societies Annual Meetingbenzinga.com - June 21 at 5:46 PMNextCure (NASDAQ: NXTC)fool.com - June 21 at 5:46 PMNextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meetingfinance.yahoo.com - June 21 at 5:46 PMNextCure Provides Business Update and Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 4 at 7:16 PMNextCure to Present at 22nd Annual Needham Virtual Healthcare Conferencefinance.yahoo.com - April 11 at 8:09 AMNextCure, Inc. (NXTC) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - March 12 at 4:55 PMNextCure Provides Business Update and Reports Full Year 2022 Financial Resultsfinance.yahoo.com - March 3 at 2:22 AMNextCure to Present at SVB Securities Global Biopharma Conferencefinance.yahoo.com - February 7 at 10:46 AM Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address The World's First "$20 Trillion Drug?" (Ad)One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%! Get the name of the stock here >>> NXTC Media Mentions By Week NXTC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NXTC News Sentiment▼0.000.41▲Average Medical News Sentiment NXTC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NXTC Articles This Week▼20▲NXTC Articles Average Week Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APLM News Today CLNN News Today BOLT News Today RMTI News Today AADI News Today MRKR News Today JAGX News Today PMN News Today JAN News Today CARA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NXTC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
